US20160358683A1 - Process for producing gallium-68 through the irradiation of a solution target - Google Patents
Process for producing gallium-68 through the irradiation of a solution target Download PDFInfo
- Publication number
- US20160358683A1 US20160358683A1 US15/172,905 US201615172905A US2016358683A1 US 20160358683 A1 US20160358683 A1 US 20160358683A1 US 201615172905 A US201615172905 A US 201615172905A US 2016358683 A1 US2016358683 A1 US 2016358683A1
- Authority
- US
- United States
- Prior art keywords
- solution
- conduit
- exchanger
- strong
- way valve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- B01J39/043—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/04—Processes using organic exchangers
- B01J39/05—Processes using organic exchangers in the strongly acidic form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/16—Organic material
- B01J39/18—Macromolecular compounds
-
- B01J41/043—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/04—Processes using organic exchangers
- B01J41/05—Processes using organic exchangers in the strongly basic form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/12—Macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B58/00—Obtaining gallium or indium
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/04—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators
- G21G1/10—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by bombardment with electrically charged particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
- G21G2001/0021—Gallium
Definitions
- the present invention relates generally to the field of radiopharmaceutical production. More particularly, the present invention relates to a process for the production of 68 Gallium radioisotope from a suitable solution target irradiated by an accelerated particle beam.
- the invention also relates to a disposable cartridge for purifying and concentrating the Gallium-68 produced by the irradiation of a isotopically enriched Zinc solution target by an accelerated particle beam.
- Gallium-68 ( 68 Ga) is of special interest for the production of Ga-radiolabelled compounds used as tracer molecules in positron emission tomography (PET) imaging technique.
- 68 Ga forms stable complexes with chelating agents, like DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and HBED-CC (N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diaceticacid) for example.
- 68 Gallium tracers may be used for brain, heart, bone, lung or tumor imaging.
- 68 Ga the most common technique is the use of a 68 Ge/ 68 Ga generator.
- 68 Ge/ 68 Ga generators can only produce small quantities of 68 Ga per elution, suffer from limited lifetime and present the risk of contaminating the final preparation with the long-lived parent nuclide 68 Ge.
- 68 Ga is also produced in a cyclotron via the 68 Zn(p,n) 68 Ga reaction in a metal (solid) target.
- the parent compound 68 Zn is deposited as solid phase on a metallic substrate that is irradiated with a proton beam. After irradiation, the target is dissolved in a strong acid solution to obtain a solution that is then purified to obtain 68 Ga.
- the process involves many time consuming steps, requires expensive hardware including solid targets and special systems to transport the irradiated target from cyclotron to the processing area and poses radioprotection issues of handling the materials after irradiation as well as liquid waste handling. This process is prone to contamination by metallic ions that can compromise the purification of the 68 Ga and subsequent labeling reaction.
- the cation-exchange column is afterwards washed, and a step of elution of 68 Zn is performed in order to recover the 68 Zn that can be purified afterwards and used in a next irradiation.
- a final elution of 68 Ga is thereafter performed with 3N HCl to a product vial.
- the present invention aims at providing a process that overcomes the above-discussed drawbacks of the prior art.
- the process according to the invention comprises the following steps:
- the process is characterized in that a step of diluting the irradiated target solution comprising zinc with water is performed after irradiation of the target solution comprising zinc and before feeding the irradiated target solution into the strong cation exchanger, the irradiated target solution being diluted at least 5 times its volume with water.
- the authors have surprisingly found that the overall quantity of 68 Ga radionucleide recovered after separation and purification is greatly enhanced when the irradiated target solution is diluted at least 5 times its volume with water.
- the inventors have surprisingly found that, when the irradiated target is diluted 5 volume times, the retention of 68 Gallium on the strong cation exchanger is greatly improved and the majority of 68 Gallium is adsorbed on the exchanger, while the Zinc tends towards being eluted more easily. Accordingly, the overall yield of the process is greatly improved.
- the overall quantity of 68 Ga purified and recovered by the method according to the invention allows an economically viable process to produce 68 Ga for the facilities that have a particle accelerator like a cyclotron on-site.
- the eluted solution comprising 68 Ga is complemented with hydrochloric acid solution to obtain a complemented solution, this complementation being performed before feeding said eluted solution into the strong anion exchanger.
- a disposable cassette that enables correct implementation of the method for purifying and concentrating Gallium-68.
- the disposable cassette should be used easily, and should be easy to maintain and service.
- the disposable cassette according to the invention may be used in connection with a device for synthesis of radiopharmaceuticals products.
- a disposable cassette according to the invention comprises:
- the cassette furthermore comprises a dilution vial connected by a fifth conduit to a bottle containing water.
- the disposable cassette is furthermore characterized in that the dilution vial is connected by a sixth conduit to the outlet of a target containing a target solution comprising zinc.
- the disposable cassette is furthermore characterized in that the first conduit comprises a second end connected to the dilution vial.
- Such disposable cassette is particularly suitable for performing the purification and concentration steps of a method according to the invention.
- FIG. 1 shows a flow chart which represents a process according to the invention.
- FIG. 2 shows a schematic view of a disposable cassette according to a first embodiment of the invention.
- FIG. 3 shows a schematic view of a disposable cassette according to a second embodiment of the invention.
- the target solution is a target solution comprising 68 Zn, and more preferentially a target solution comprising isotopically enriched 68 Z.
- the target solution is irradiated by a proton beam.
- the present invention is intended to be used preferably with a cyclotron apparatus, which delivers high energy proton beams.
- the target solution ( 10 ) may comprises a zinc salt selected among zinc nitrate, zinc chloride, zinc chlorate, zinc bromide, zinc iodide, zinc sulfate.
- the zinc salt may be diluted in nitric acid or hydrochloric acid.
- the target solution ( 10 ) is a Zinc-68 nitrate solution diluted in low concentrated nitric acid solution, for avoiding precipitation of zinc nitrate.
- the target is an isotopically enriched 1.7 M solution of 68 zinc nitrate in 0.2 N nitric acid in a closed target system.
- the target may for example be any Nirta® Conical target sold by Ion Beam Applications, Louvain-La-Neuve, Belgium.
- the target system may also be the target system as described in international patent publication WO 2012/055970.
- the target containing the target solution ( 20 ) is irradiated by an accelerated particle beam.
- the accelerated particle beam is a proton beam when the zinc target is isotopically enriched 68 Zn.
- the proton beam is produced by a cyclotron, for example a low or mid energy cyclotron producing a proton beam in the range of 12 to 30 MeV.
- the irradiation step may last around 30 min at a beam of current of 20 ⁇ A.
- the overall volume of the target solution comprising zinc or 68 Zinc may be comprised between 0.5 mL and 10 mL.
- the irradiated target solution is received in a collection vial. There, the irradiated target is diluted (step ⁇ ) in water to obtain a diluted solution ( 20 ).
- the dilution of the irradiated target solution is at least 5 volume times the volume of the solution comprising the irradiated target.
- the irradiated solution target ( 10 ) is diluted at least 10 times. For example, when the overall volume of the irradiated target solution comprising zinc is around 1 mL, the volume of the diluted solution ( 20 ) is around 5 mL.
- the dilution of the irradiated target solution is comprised between 5 and 15 volume times, more preferably between 10 and 15 volume times.
- the inventors have surprisingly found that the process is less efficient when lower dilution volumes than 5 volume times are used. Moreover, higher volumes increase process time, and thus loss of Gallium-68 isotope by radioactive decay.
- This step of dilution allows achieving high 68 Gallium adsorption yields into a strong cation exchanger ( 30 ). Indeed, over 90% of the total 68 Gallium comprised in the diluted solution ( 20 ) is adsorbed on the strong cation exchanger ( 30 ) during the step of feeding (step b) the diluted solution into the strong cation exchanger ( 30 ). When one dilutes the irradiated solution with a lower volume times, adsorption of 68 Gallium into the strong cation exchanger is reduced, and the overall yield of the process is therefore lower.
- the diluted solution ( 20 ) is afterwards fed (step b) into a strong cation exchanger ( 30 ) where the 68 Gallium isotope is adsorbed (or trapped) on the strong cation exchanger (also known as SCX) ( 30 ).
- a strong cation exchanger 30
- SCX strong cation exchanger
- the diluted solution ( 20 ) is passed through the exchanger ( 30 ).
- the exchanger ( 30 ) may be a strong cationic column loaded with a strong acid cation resin containing DVB (divinylbenzene).
- the strong cation exchanger ( 30 ) may be preconditioned firstly with 3M hydrochloric acid solution and then by washing the exchanger with water.
- 3M hydrochloric acid solution For example, for about 1400 mg of resin exchanger, between 3 mL and 10 mL, preferentially about 5 mL, of hydrochloric acid 3M solution followed by between 5 mL and 15 mL, preferentially about 10 mL, of water may be used during the preconditioning of the exchanger ( 30 ), eventually followed by air in order to dry the exchanger.
- a greater volume of water may be used when preconditioning the exchanger.
- the exchanger is washed (step c).
- the exchanger is washed with water ( 100 ), and more preferentially with chelexed water to avoid the presence of any undesirable contaminants.
- This washing step allows removing certain type of contaminants, like 11 C and 13 N isotopes.
- the volume of the washing solution may be dependent from the volume of the irradiated target ( 10 ) and/or the weight of the exchanger ( 30 ). For example, when the weight of the exchanger ( 30 ) is about 1400 mg, about 5 mL of water may be used to wash the strong cation exchanger ( 30 ). Of course, a greater volume may be used. It should also be understood that a plurality of washing steps may be performed.
- Zinc isotopes are eluted (step d) from the strong cation exchanger.
- the Zinc isotopes may be recovered in a vial for optional Zn purification and reuse.
- the Zinc elution solution ( 200 ) used for this step should comprise acetone.
- the Zn elution solution ( 200 ) is 80% acetone, and in a more preferred embodiment, the Zn elution solution ( 200 ) is 0.5 M hydrobromic acid (HBr) in 80% acetone solution.
- the volume of the Zn elution solution ( 200 ) needed to perform this washing step may be dependent from the volume of the irradiated target ( 10 ) and/or the weight of the strong cation exchanger ( 30 ) and/or the molarity of the acetone solution ( 300 ).
- the weight of the exchanger is about 1400 mg and the solution is 80% acetone, between 10 mL and 50 mL, preferentially about 30 mL, of the Zn elution solution ( 200 ) may be used.
- greater volume of the Zn elution solution may be used.
- step e the strong cation exchanger is performed.
- This step may be performed with water or chelexed water, like the first washing step described above. The purpose of this step is to remove traces of acetone and eventually HBr when the Zn elution solution ( 200 ) is hydrobromic acid in 80% acetone solution.
- a step of elution (step f) of the 68 Gallium from the strong cation exchanger ( 30 ) is performed to obtain an eluted solution ( 40 ).
- a hydrochloric acid solution ( 300 ) should be used when performing this step of the process.
- the hydrochloric acid solution ( 300 ) has a molarity comprised between 1 M and 5 M, preferentially between 2 M and 4 M, and more preferentially between 2.8 M and 3.2 M, and still more preferentially a molarity about 3 M.
- the volume of the hydrochloric acid solution ( 300 ) may be dependent from the weight of the strong cation exchanger ( 30 ) and/or the molarity of the hydrochloric acid solution ( 300 ). For example, when the weight of the strong cation exchanger ( 30 ) is about 1400 mg and the molarity of the hydrochloric acid solution ( 300 ) is about 3 M, between 5 mL and 10 mL, preferentially about 7 mL, of hydrochloric acid solution may be used when performing this step of the process. Of course, greater volume of hydrochloric solution may be used when one performs this step of the process.
- the eluted solution ( 40 ) is collected into a collection vial or reservoir.
- an optional additional step of complementing the eluted solution ( 40 ) with another hydrochloric acid solution ( 350 ) is performed before feeding the eluted solution ( 40 ) into the strong anion exchanger (also known as SAX) ( 50 ).
- This hydrochloric acid solution ( 350 ) may be about 12 M.
- the purpose of the complementation is to decrease/adjust the pH of the eluted solution ( 40 ).
- hydrochloric acid is added to the eluted solution ( 40 ) until the molarity of the hydrochloric acid in the complemented solution is comprised between 7 M and 10 M, preferentially between 7.5 M and 9 M, more preferentially between 7.5 M and 8.5 M, and most preferentially about 8 M.
- the eluted solution ( 40 ) or the complemented solution comprising 68 Gallium is thereafter fed (step g) into a strong anionic exchanger (SAX) ( 50 ).
- SAX strong anionic exchanger
- this exchanger ( 50 ) may be a strong anionic column loaded with a strong anion resin like BIORAD AG1X8 (Bio-Rad laboratories, Hercules, Calif., USA) and the like.
- the strong anion exchanger (SAX) ( 50 ) may be preconditioned with 8M HCl before feeding (step g) the eluted solution ( 40 ) or the complemented solution into the strong anion exchanger (SAX) ( 50 ).
- the strong anion exchanger (SAX) ( 50 ) is preconditioned with chelexed water followed by hydrochloric acid solution with a molarity comprised between 7 M and 10 M, preferentially between 7.5 M and 9 M, more preferentially between 7.5 M and 8.5 M, and most preferentially about 8 M.
- the strong anion exchanger (SAX) ( 50 ) is washed (step h) in order to elute impurities like traces of hydrochloric acid and/or to ensure correct pH of the final solution ( 60 ).
- the washing solution used in this step (step h) may be water.
- this step is performed with ethanol solution, like 95% ethanol ( 400 ).
- the volume of the washing solution may be dependent on the mass of the strong anion exchanger and/or the molarity of the ethanol solution. For example, when the mass of the strong anion exchanger is about 400 mg, between 0.5 mL and 2 mL, preferentially about 1 ml, of 95% ethanol solution may be used to perform the washing step (step h).
- the 68 Gallium isotope is finally eluted (step i) from the strong anion exchanger ( 50 ).
- a solution of hydrochloric acid ( 400 ) is used to perform this step.
- the molarity of the hydrochloric acid solution ( 400 ) is comprised between 0.08 M and 1.2 M, more preferentially about 0.1 M.
- the final solution ( 60 ) comprises highly purified and concentrated 68 Gallium isotope, preferentially in 0.1 M hydrochloric acid, and is ready to use for a further incorporation of 68 Ga isotope into tracers molecules, like DOTA-TOC, DOTA-NOC, DOTA-TATE, PSMA-H BED-CC.
- the 68 Ga isotope may be incorporated into tracer molecules that comprise a chelator selected among DOTA, PSMA, NOPO, TRAP, THP (trishydroxy-pyrydinones), PCTA, AAZTA, DATA, dedpa, FSC, NODAGA and the like.
- a chelator selected among DOTA, PSMA, NOPO, TRAP, THP (trishydroxy-pyrydinones), PCTA, AAZTA, DATA, dedpa, FSC, NODAGA and the like.
- the overall time to perform the process according to the invention is about 45 min.
- highly pure and concentrated 68 Ga isotope in 0.1 M hydrochloric acid solution is obtained.
- the process according to the invention achieves more than 100 mCi of pure 68 Ga.
- the final solution is ready to be used on labelling peptides.
- the 68 Ga isotope purified and concentrated according to the process of the invention may be incorporated into tracer molecules according to the following steps:
- the solution comprising highly purified and concentrated 68 Gallium (in 0.1 M HCl) is fed into a pre-conditioned (1 mL of 4 M HCl, 10 mL of H2O) cation exchange SCX column.
- the column is dried with a stream of N2 to remove any traces of HCl.
- 68 Ga is eluted.
- the elution solution should comprise acetone.
- the elution solution is 98% acetone
- the elution solution is 0.02M hydrochloric acid (HCl) in 98% acetone solution.
- the volume of the elution solution needed to perform this washing step may be dependent from the weight of the strong cation exchanger.
- a C18 column (or C18 cartridge) is a HPLC (high performance liquid chromatography) columns that use a C18 substance as the stationary phase.
- the inventors found that cooling the 68 Ga-peptide mixture is critical as it reduces substantially the radiolabelled peptide losses during purification.
- After a washing step with 5 mL of sterile water the 68 Ga-peptide complex is eluted from the cartridge with 1 mL of 75% ethanol followed by 9 mL of saline solution to obtain the very pure 68 Ga-peptide.
- the product is then sterilized by filtration through a 0.22 ⁇ m membrane filter and transferred to the final vial. The final product is ready to use in a PET method.
- the 68 Ga isotope purified and concentrated according to the process of the invention may be incorporated into tracers molecules according to the following steps:
- the strong cation exchanger may be a strong cationic column loaded with a strong acid cation resin containing DVB (divinylbenzene).
- DVB dibenzene
- DOWEX 50WX8 Dow Chemical Co., Midlands, Mich., USA
- AG 50W-X8 BioRad Laboratories, Hercules, Calif., USA
- the mixture of acetone and hydrochloric acid may be a acetone (98%)/Hydrochloric acid 0.02 N solution. About 1 mL of the mixture may be used to elute 68 Gallium isotope.
- the invention also concerns a disposable cassette able to perform the dilution, purification and concentration steps according to the method of the invention.
- a disposable cassette according to a first embodiment of the invention is illustrated on FIG. 2 .
- This disposable cassette comprises a dilution vial ( 505 ) connected by a fifth conduit ( 650 ) to a bottle ( 651 ) containing water.
- the disposable cassette ( 500 ) is furthermore characterized in that the dilution vial ( 505 ) is connected by a sixth conduit ( 660 ) to the outlet ( 661 ) of the 68 Zn target.
- the disposable cassette ( 500 ) is furthermore characterized in that the first conduit ( 610 ) comprises a second end connected to the dilution vial ( 505 ).
- the cassette may be plugged in and out of a device for synthesis of radiopharmaceuticals products from chemical reagents.
- the device for synthesis of radiopharmaceuticals may be a device that is able to perform the above described incorporation of 68 Ga isotope into tracer molecules.
- the disposable cassette is dedicated to operate with different type of synthesizers driven by an automated controller.
- the synthesizer may be the SYNTHERA® platform sold by ION BEAM APPLICATION, Louvain-La-Neuve, Belgium.
- the device may also be the one described in the patent EP1343533.
- This device enables the different chemical compounds for carrying out the synthesis of radiopharmaceutical compounds to be brought into contact during reaction and allows purification of the product.
- the device for synthesis of radiopharmaceutical compounds and the disposable cassette ( 500 ) when plugged to the device may be linked to an automaton which controls the various operations enabling the performance of the purification and concentration of 68 Ga, and the synthesis of pharmaceutical compounds.
- Pump means may be located on the disposable cassette ( 500 ) and/or on the synthesizer.
- the pump means may be syringe pumps connected to at least some of the conduits to draw and pump fluid through the conduits. A man skilled in the art is able to determine where such syringe pumps may be implanted on the disposable cassette.
- a syringe pump may be implanted on each conduit.
- An automated controller is programmed to operate pumps and valves, and control the provisions of the various chemical reagents for a correct purification and concentration of the Gallium-68.
- the liquid is pumped through the conduits by a vacuum or by a syringe pump.
- desired location for example one of the cationic exchanger
- a 3-way valve is actioned and the liquid is therefore pumped to a disposable vial (or waste vial) when the liquid is a washing liquid, or a liquid comprising impurities.
- the disposable cassette ( 500 ) may comprise securing means which enable it to be fixed to the synthesizer.
- the securing means can take the form of fasteners arranged according to a precise configuration. It should be understood that, when the disposable cassette is connected to the synthesizer, both devices are in fluid communication through an outlet ( 999 ) of the cassette.
- the cassette is removable from the synthesizer. For example, the disposable cassette is cooperatively engaged with the synthesizer to drive the fluids from the output line of a cyclotron to the synthesizer.
- the steps of purification and concentration of the Gallium-68 are performed within the disposable cassette, while the incorporation of the Gallium-68 into radiopharmaceuticals is performed within the synthesizer.
- the disposable cassette ( 500 ) is removed after the synthesis run and may be replaced by a fresh cassette. Alternatively, some elements of the disposable cassette may be replaced, like the chemical reagents or the cation exchangers, while the other elements of the cassette are washed to remove any trace of the previous run.
- the disposable cassette ( 500 ) may comprise a rigid portion (e.g. an ABS plate) on which the various components of the disposable cassette ( 500 ) are arranged and fixed.
- one first bottle ( 530 a ) comprises water; one other first bottle ( 530 b ) comprises acetone; and one other first bottle ( 530 c ) comprises hydrochloric acid.
- one second bottle ( 540 a ) comprises water and one other second bottle ( 540 b ) comprises hydrochloric acid.
- the disposable device ( 500 ) may comprise a support plate, for example in ABS, for supporting the elements constituting the disposable device.
- the conduits ( 610 , 620 , 630 , 640 , 650 , 660 ) may be flexible tubes like silicone tubes, channels molded or drilled in a support plate.
- the bottles may be pre-metered bottles.
- the conduits may be linked to mechanical means acting on the said conduits and enabling to monitor and control mechanically the transfer of the chemical reagents, the various solutions (irradiated solution target, diluted solution, eluted solution, final solution) between their respective compartments.
- mechanical means may comprise:
- the pure product is taken out from the disposable cassette and dispatched to a synthesizer that will incorporate Gallium-68 into radiopharmaceuticals.
- the disposable cassette ( 500 ) furthermore comprises another optional bottle ( 550 ) containing hydrochloric acid connected directly to the elution vial ( 501 ). This allows for complementation of the eluted solution with hydrochloric acid before feeding the eluted solution into the strong anion exchanger ( 900 ).
- the first conduit comprises two first 3-way valves ( 710 , 711 ).
- One of the first 3-way valves ( 710 ) is connected to at least two bottles of reagent ( 530 a, 530 b ).
- the other first 3-way valve ( 711 ) is connected to a third bottle of reagent ( 530 c ).
- This embodiment allows the separation of reagents reserved for washing the strong cation exchanger ( 800 ) and removing impurities, like 68 Zn, from the strong cation exchanger ( 800 ) on one hand, and the reagents, like hydrochloric acid, reserved for eluting 68 Ga isotope from the strong cation exchanger ( 800 ).
- the eluted solution contains less impurity when the disposable cassette ( 500 ) according to this embodiment is used.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Metallurgy (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Particle Accelerators (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/998,846 US10600528B2 (en) | 2015-06-05 | 2018-08-17 | Process for producing Gallium-68 through the irradiation of a solution target |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15170854.2 | 2015-06-05 | ||
EP15170854.2A EP3101660B1 (de) | 2015-06-05 | 2015-06-05 | Verfahren zur herstellung von gallium-68 durch bestrahlung eines flüssigtargets |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/998,846 Division US10600528B2 (en) | 2015-06-05 | 2018-08-17 | Process for producing Gallium-68 through the irradiation of a solution target |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160358683A1 true US20160358683A1 (en) | 2016-12-08 |
Family
ID=53298231
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/172,905 Abandoned US20160358683A1 (en) | 2015-06-05 | 2016-06-03 | Process for producing gallium-68 through the irradiation of a solution target |
US15/998,846 Active 2036-08-09 US10600528B2 (en) | 2015-06-05 | 2018-08-17 | Process for producing Gallium-68 through the irradiation of a solution target |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/998,846 Active 2036-08-09 US10600528B2 (en) | 2015-06-05 | 2018-08-17 | Process for producing Gallium-68 through the irradiation of a solution target |
Country Status (5)
Country | Link |
---|---|
US (2) | US20160358683A1 (de) |
EP (1) | EP3101660B1 (de) |
JP (1) | JP6632472B2 (de) |
CA (1) | CA2932118C (de) |
PT (1) | PT3101660T (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108126648A (zh) * | 2018-01-04 | 2018-06-08 | 江苏华益科技有限公司 | 一种放射性药物的自动传输装置及方法 |
WO2021070164A1 (en) * | 2019-10-12 | 2021-04-15 | Artms Products, Inc. | Systems and methods of isolation of gallium-68 |
CN113019279A (zh) * | 2021-03-11 | 2021-06-25 | 山西医科大学第一医院 | 一种放射性药物制备的自动合成装置及其使用方法 |
CN113144225A (zh) * | 2021-03-30 | 2021-07-23 | 广东回旋医药科技股份有限公司 | 一种高放射性核纯度的68Ga-GaCl3溶液的制备方法及应用 |
CN113200564A (zh) * | 2021-04-09 | 2021-08-03 | 广东回旋医药科技股份有限公司 | 一种[68Zn]硝酸锌靶溶液的制备方法及应用 |
CN113272917A (zh) * | 2018-09-03 | 2021-08-17 | 奥斯陆大学 | 用于生产镓放射性核素的方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3071449A1 (en) * | 2017-07-31 | 2019-02-07 | Stefan Zeisler | System, apparatus and method for producing gallium radioisotopes on particle accelerators using solid targets and ga-68 composition produced by same |
WO2020030659A1 (en) | 2018-08-07 | 2020-02-13 | Technical University Of Denmark | Separation of radiometals |
CA3122862A1 (en) | 2018-12-11 | 2020-06-18 | Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Et Genie S.E.C. | Processes and systems for producing and/or purifying gallium-68 |
CN112614607A (zh) * | 2020-12-02 | 2021-04-06 | 中广核研究院有限公司 | 放射性核素锰-54的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090218286A1 (en) * | 2005-10-13 | 2009-09-03 | Bisschops Marc Antonius T | Device for chromatographic separations |
US20120307953A1 (en) * | 2011-06-02 | 2012-12-06 | Nigel Raymond Stevenson | General Radioisotope Production Method Employing PET-Style Target Systems |
US8894860B2 (en) * | 2010-07-14 | 2014-11-25 | Institute Of Nuclear Energy Research, Atomic Energy Council, Executive Yuan | Gallium-68 radioisotope generator and generating method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1216715A1 (de) | 2000-12-22 | 2002-06-26 | Ion Beam Applications S.A. | Synthetisierungsvorrichtung von Radiopharmaca |
US7586102B2 (en) * | 2006-08-14 | 2009-09-08 | Board Of Regents The University Of Texas System | Automated system for formulating radiopharmaceuticals |
US7728310B2 (en) * | 2007-05-10 | 2010-06-01 | Los Alamos National Security, Llc | Method for the chemical separation of GE-68 from its daughter Ga-68 |
JP2009229201A (ja) * | 2008-03-21 | 2009-10-08 | Institute Of Physical & Chemical Research | Gaのイオンを単離する方法とそのための装置 |
BE1019556A3 (fr) | 2010-10-27 | 2012-08-07 | Ion Beam Applic Sa | Dispositif destine a la production de radioisotopes. |
EP3142709A4 (de) * | 2014-05-15 | 2017-12-20 | Mayo Foundation for Medical Education and Research | Lösungsziel für die zyklotronherstellung von radiometallen |
-
2015
- 2015-06-05 PT PT151708542T patent/PT3101660T/pt unknown
- 2015-06-05 EP EP15170854.2A patent/EP3101660B1/de active Active
-
2016
- 2016-06-02 JP JP2016110824A patent/JP6632472B2/ja active Active
- 2016-06-03 CA CA2932118A patent/CA2932118C/en active Active
- 2016-06-03 US US15/172,905 patent/US20160358683A1/en not_active Abandoned
-
2018
- 2018-08-17 US US15/998,846 patent/US10600528B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090218286A1 (en) * | 2005-10-13 | 2009-09-03 | Bisschops Marc Antonius T | Device for chromatographic separations |
US8894860B2 (en) * | 2010-07-14 | 2014-11-25 | Institute Of Nuclear Energy Research, Atomic Energy Council, Executive Yuan | Gallium-68 radioisotope generator and generating method thereof |
US20120307953A1 (en) * | 2011-06-02 | 2012-12-06 | Nigel Raymond Stevenson | General Radioisotope Production Method Employing PET-Style Target Systems |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108126648A (zh) * | 2018-01-04 | 2018-06-08 | 江苏华益科技有限公司 | 一种放射性药物的自动传输装置及方法 |
CN113272917A (zh) * | 2018-09-03 | 2021-08-17 | 奥斯陆大学 | 用于生产镓放射性核素的方法 |
WO2021070164A1 (en) * | 2019-10-12 | 2021-04-15 | Artms Products, Inc. | Systems and methods of isolation of gallium-68 |
CN114761100A (zh) * | 2019-10-12 | 2022-07-15 | 阿尔特姆斯产品公司 | 分离镓-68的系统和方法 |
EP4041426A4 (de) * | 2019-10-12 | 2022-11-23 | Artms Products, Inc. | Systeme und verfahren zur isolierung von gallium-68 |
CN113019279A (zh) * | 2021-03-11 | 2021-06-25 | 山西医科大学第一医院 | 一种放射性药物制备的自动合成装置及其使用方法 |
CN113144225A (zh) * | 2021-03-30 | 2021-07-23 | 广东回旋医药科技股份有限公司 | 一种高放射性核纯度的68Ga-GaCl3溶液的制备方法及应用 |
CN113200564A (zh) * | 2021-04-09 | 2021-08-03 | 广东回旋医药科技股份有限公司 | 一种[68Zn]硝酸锌靶溶液的制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
PT3101660T (pt) | 2017-09-18 |
JP6632472B2 (ja) | 2020-01-22 |
CA2932118A1 (en) | 2016-12-05 |
EP3101660B1 (de) | 2017-08-09 |
US10600528B2 (en) | 2020-03-24 |
EP3101660A1 (de) | 2016-12-07 |
US20190013108A1 (en) | 2019-01-10 |
JP2017003577A (ja) | 2017-01-05 |
CA2932118C (en) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10600528B2 (en) | Process for producing Gallium-68 through the irradiation of a solution target | |
US7087206B2 (en) | Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine | |
US8147804B2 (en) | Method and device for isolating a chemically and radiochemically cleaned 68Ga-radionuclide and for marking a marking precursor with the 68Ga-radionuclide | |
DK2546839T3 (en) | Process for the preparation of carrier-free, extremely pure 177Lu compounds and carrier-free 177Lu compounds | |
McAlister et al. | Automated two column generator systems for medical radionuclides | |
US10020086B2 (en) | Method and apparatus for the production of lead 212 for medical use | |
EP2059808A1 (de) | Automatisiertes system zur formulierung von radiopharmaka | |
Alnahwi et al. | Automated radiosynthesis of 68Ga for large-scale routine production using 68Zn pressed target | |
KR20040075883A (ko) | 수용액 중의 금속 원소의 이온을 분리하는 방법 및 장치 | |
US11417439B2 (en) | Rapid isolation of cyclotron-produced gallium-68 | |
US11986815B2 (en) | Processes and systems for producing and/or purifying gallium-68 | |
US20180158559A1 (en) | Method and system for producing gallium-68 radioisotope by solid targeting in a cyclotron | |
US5729821A (en) | Concentration of perrhenate and pertechnetate solutions | |
Fukumura et al. | Practical production of 61Cu using natural Co target and its simple purification with a chelating resin for 61Cu-ATSM | |
Guseva | Radioisotope generators of short-lived α-emitting radionuclides promising for use in nuclear medicine | |
KR101041181B1 (ko) | Cu-64를 제조하기 위해 Cu-64가 형성된 Ni-64 농축 표적으로부터 Cu-64를 분리하는 방법 | |
CN107405538B (zh) | 用于从来源于68Ge/68Ga发生器的洗脱物纯化Ga-68的工艺和用于所述工艺中的色谱柱 | |
RU2522892C1 (ru) | Способ получения активной фармацевтической субстанции для синтеза препаратов галлия-68 | |
Fonseca et al. | GMP-Automated Purification of Copper-61 Produced in Cyclotron Liquid Targets: Methodological Aspects | |
US20230357100A1 (en) | Method for producing radioactive labeled substance, device for producing radioactive labeled substance, and method for evaporatively concentrating radioactive metal nuclide | |
Knapp Jr | The development and use of radionuclide generators in nuclear medicine. Recent advances and future perspectives | |
Ruiz Quiros | A Chromatographic Method to Separate Sc (III) from Zn (II) Ions: A Step in the Purification of Sc-44 (an isotope of medical interest) | |
Dabrowski et al. | Radionuclide impurities in cyclotron-produced gallium-68 and zirconium-89 for positron emission tomography | |
Fadzil et al. | Purification and concentration of gallium-68 via anion exchange method from a SnO2-based column germanium-68/gallium-68 generator | |
WO2024050168A2 (en) | Systems and methods for generating radionuclides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ION BEAM APPLICATIONS S.A., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ABRUNHOSA, ANTERO;ALVES, VITOR;ALVES, FRANCISCO;REEL/FRAME:038802/0171 Effective date: 20160206 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |